Haemophilus influenza (Hib)- Type B Infection Drug Development Pipeline Study, H2 2018
Haemophilus influenza (Hib) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Haemophilus influenza (Hib) Infection pipeline products.
DISEASE OVERVIEW
Haemophilus influenza bacteria (Hib) often causes various types of infections ranging from mild to serious levels such as infections in skin, ear infections, lungs, blood, Meningitis, Epiglotittis etc. Maximum incidence of the infection is observed among young children.
Haemophilus influenza is classified into two types%li%unencapsulated and encapsulated, which are further divided into different serotypes. Of these the serotype b accounts for 95% of all invasive infections caused by the bacteria.
As these infections are similar to the ones caused by other bacteria, quick and accurate diagnosis is challenging. Mass vaccination programs are being conducted to prevent the spread of Hib infections. Cephalosporins are primarily administered to patients infected with the bacteria.
15+ companies are currently participating in the pipeline development of Haemophilus influenza bacterial infection pipeline (Hib) including Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Novo Medi Sciences Pvt Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi Pasteur SA, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.
REPORT DESCRIPTION
The Haemophilus influenza (Hib) Infection pipeline guide presents complete overview of drugs currently being developed for Haemophilus influenza (Hib) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Haemophilus influenza (Hib) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Haemophilus influenza (Hib) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Haemophilus influenza (Hib) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Haemophilus influenza (Hib) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Haemophilus influenza (Hib) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Haemophilus influenza (Hib) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Haemophilus influenza bacteria (Hib) often causes various types of infections ranging from mild to serious levels such as infections in skin, ear infections, lungs, blood, Meningitis, Epiglotittis etc. Maximum incidence of the infection is observed among young children.
Haemophilus influenza is classified into two types%li%unencapsulated and encapsulated, which are further divided into different serotypes. Of these the serotype b accounts for 95% of all invasive infections caused by the bacteria.
As these infections are similar to the ones caused by other bacteria, quick and accurate diagnosis is challenging. Mass vaccination programs are being conducted to prevent the spread of Hib infections. Cephalosporins are primarily administered to patients infected with the bacteria.
15+ companies are currently participating in the pipeline development of Haemophilus influenza bacterial infection pipeline (Hib) including Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Novo Medi Sciences Pvt Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi Pasteur SA, Tianjin CanSino Biotechnology Inc and Wockhardt Ltd.
REPORT DESCRIPTION
The Haemophilus influenza (Hib) Infection pipeline guide presents complete overview of drugs currently being developed for Haemophilus influenza (Hib) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Haemophilus influenza (Hib) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Haemophilus influenza (Hib) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Haemophilus influenza (Hib) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Haemophilus influenza (Hib) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Haemophilus influenza (Hib) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Haemophilus influenza (Hib) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE REPORT INCLUDES
- Panorama of Haemophilus influenza (Hib) Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Haemophilus influenza (Hib) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Haemophilus influenza (Hib) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Haemophilus influenza (Hib) Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Haemophilus influenza (Hib) Infection pipeline therapeutics
- Get clear understanding of the entire Haemophilus influenza (Hib) Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Haemophilus influenza (Hib) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Haemophilus influenza (Hib) Infection Pipeline include-
Number of Companies with Haemophilus influenza (Hib) Infection projects in pre-clinical Development-
Number of Companies with Haemophilus influenza (Hib) Infection projects in Clinical Development-
Haemophilus influenza (Hib) Infection Pipeline Companies based in Americas
Haemophilus influenza (Hib) Infection Pipeline Companies based in Europe
Haemophilus influenza (Hib) Infection Pipeline Companies based in Asia Pacific
Haemophilus influenza (Hib) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Haemophilus influenza (Hib) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Haemophilus influenza (Hib) Infection Pipeline Agents in Clinical Development stage
Haemophilus influenza (Hib) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Haemophilus influenza (Hib) Infection Pipeline agents
II. INSIGHTS INTO HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE
1. Disease Overview
Introduction to Haemophilus influenza (Hib) Infection
Symptoms and Causes of Haemophilus influenza (Hib) Infection
Treatment or Prevention Options for Haemophilus influenza (Hib) Infection
Other Details
2. Phase wise Pipeline Compounds
Haemophilus influenza (Hib) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 1 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 2 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 3 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Haemophilus influenza (Hib) Infection Pipeline Compounds
4. Haemophilus influenza (Hib) Infection Pipeline by Mechanism of Action
III. HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
Haemophilus influenzae B vaccine
BK1310
Liquid Hexavalent Vaccine
Pentavalent (DTP-Hib-HepB) vaccine
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DTwP-Hb-Hib pentavalent vaccine
LBVD
(Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenzae type b ) pentavalent vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
(diphtheria, tetanus, pertussis, poliomyelitis, haemophilus influenzae type B) vaccine
MCV2 Hib
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Biological E Ltd
Cadila Healthcare Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi Pasteur SA
Tianjin CanSino Biotechnology Inc
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Haemophilus influenza (Hib) Infection Pipeline include-
Number of Companies with Haemophilus influenza (Hib) Infection projects in pre-clinical Development-
Number of Companies with Haemophilus influenza (Hib) Infection projects in Clinical Development-
Haemophilus influenza (Hib) Infection Pipeline Companies based in Americas
Haemophilus influenza (Hib) Infection Pipeline Companies based in Europe
Haemophilus influenza (Hib) Infection Pipeline Companies based in Asia Pacific
Haemophilus influenza (Hib) Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Haemophilus influenza (Hib) Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Haemophilus influenza (Hib) Infection Pipeline Agents in Clinical Development stage
Haemophilus influenza (Hib) Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Haemophilus influenza (Hib) Infection Pipeline agents
II. INSIGHTS INTO HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE
1. Disease Overview
Introduction to Haemophilus influenza (Hib) Infection
Symptoms and Causes of Haemophilus influenza (Hib) Infection
Treatment or Prevention Options for Haemophilus influenza (Hib) Infection
Other Details
2. Phase wise Pipeline Compounds
Haemophilus influenza (Hib) Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 1 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 2 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Phase 3 stage Drugs
Haemophilus influenza (Hib) Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Haemophilus influenza (Hib) Infection Pipeline Compounds
4. Haemophilus influenza (Hib) Infection Pipeline by Mechanism of Action
III. HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
Haemophilus influenzae B vaccine
BK1310
Liquid Hexavalent Vaccine
Pentavalent (DTP-Hib-HepB) vaccine
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DTwP-Hb-Hib pentavalent vaccine
LBVD
(Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenzae type b ) pentavalent vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
(diphtheria, tetanus, pertussis, poliomyelitis, haemophilus influenzae type B) vaccine
MCV2 Hib
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Biological E Ltd
Cadila Healthcare Ltd
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi Pasteur SA
Tianjin CanSino Biotechnology Inc
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HAEMOPHILUS INFLUENZA (HIB) INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
